Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY

Journal article

HERRINGTON W., (2024), Clinical and Experimental Nephrology

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Journal article

EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

Journal article

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Journal article

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Delivering trials in the NHS: more than worth it.

Journal article

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Accelerating clinical trials: time to turn words into action.

Other

Landray MJ. et al, (2023), Lancet, 402, 165 - 168

Randomised controlled trials for mpox in endemic countries.

Journal article

Rojek A. et al, (2023), Lancet Infect Dis

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Journal article

Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Journal article

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801

Empagliflozin in Patients with Chronic Kidney Disease.

Journal article

EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med

Load More